Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein

Mita, Yuhsaku; Aoyagi, Yoshinobu; Suda, Takafumi; Asakura, Hitoshi

doi:10.1016/s0168-8278(00)80099-9

Cited by 36 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous result revealed that FUT8 levels in HCC tissue were higher than those in the surrounding non-cancerous tissues and that FUT8 levels of HCC tissue increased in accordance with tumor dedifferentiation [21]. Several reports have shown the relationship between AFP-L3 status and histologic grade in HCC.…”

Section: Discussionmentioning

confidence: 86%

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 86%

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…They are synthesized in membranebound form, but can be cleaved off from the membranes and released into body fluids. It has been shown that the amounts of some glycosyltransferases are elevated in the sera of cancer patients [19][20][21], and that β1,4-galactosyltransferase-I can serve as a tumor marker for ovarian cancer [22,23]. Recently, we developed a sandwich-ELISA method for detecting β1,3-galactosyltransferase-4/-5 and showed that it can serve as a tumor marker for uterine corpus cancer (unpublished data).…”

Section: Discussionmentioning

confidence: 99%

N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer

et al. 2009

View full text Add to dashboard Cite

N-Acetylglucosamine 6-O-sulfotransferase-2 (GlcNAc6ST2) is ectopically expressed in ovarian mucinous and clear cell adenocarcinoma [Kanoh et al., Glycoconj J 23:453-460, 2006]. Here we studied whether GlcNAc6ST2 protein can be detected in sera from patients with gynecological cancers and could serve as a tumor marker. First, we created a monoclonal antibody and polyclonal antiserum against GlcNAc6ST2. These antibodies were specific for GlcNAc6ST2, as shown by Western blot analysis and immunoprecipitation. Using these antibodies, we constructed a sandwich ELISA method for detecting GlcNAc6ST2 in the serum. GlcNAc6ST2 provided lower positive rates for ovarian cancer than CA125, but higher positive rates for uterine cervical and corpus cancer than SCC antigens and CA125, respectively. A significantly higher percentage of stage I uterine cervical and corpus cancers were positive for GlcNAc6ST2 than for SCC antigens and CA125, respectively. GlcNAc6ST2 could therefore be a good serological marker for detecting early-stage uterine cervical and corpus cancers.

show abstract

“…A direct enzymatic assay [7] indicated that both the ·1-6 fucosylated complex sugar chain and ·1-6 FucT activities were increased in various strains of established hepatoma cell lines [8]. When human liver tissue samples were investigated, ·1-6 FucT mRNA and its enzymatic activity were frequently elevated in HCC tissues as well as in adjacent nontumor liver tissues over a wide range and tended to increase with the progression of chronic liver diseases, compared to normal liver devoid of any chronic liver disease [9,10]. While ·1-6 fucosylation is involved in malignant transformation, the overexpression of ·1-6 FucT in a hepatoma cell line led to a dramatic decrease in its adhesion to fibronectin, which suppressed intrahepatic metastasis after splenic injection in athymic mice [11].…”

Section: Introductionmentioning

confidence: 99%

The Enzymatic Basis for the Conversion of Nonfucosylated to Fucosylated α-Fetoprotein by Acyclic Retinoid Treatment in Human Hepatoma Cells: Activation of α1-6 Fucosyltransferase

et al. 2002

View full text Add to dashboard Cite

The purpose of the present study was to investigate the mechanism by which nonfucosylated α-fetoprotein (AFP) is converted to fucosylated AFP in human hepatoma cell lines exposed to acyclic retinoid (AR), an effective drug for the secondary prevention of hepatocellular carcinoma. AR treatment (100 µM) of HepG2 and Hep3B cells significantly increased the activity and mRNA levels of α1-6 fucosyltransferase (α1-6 FucT), the enzyme responsible for the fucosylation of AFP, leading to an increase in fucosylated glycoproteins as evidenced by lectin binding measurements. Lectin immunoelectrophoresis of AFP obtained from culture media indicated that the relative percentage of nonfucosylated AFP (L1 fraction) was decreased and α1-6 fucosylated AFP (L3 fraction) was increased in these hepatoma cell lines after treatment with AR. The total AFP levels were, however, markedly suppressed by AR treatment, and therefore the absolute L3 fraction on the basis of the total AFP present was extremely low. These results demonstrate that AR enhances the conversion of the L1 to the L3 fraction due to the activation of α1-6 FucT in human hepatoma cell lines despite clinical outcome with AR treatment and the L3 fraction of AFP. Even though the dramatic decrease in AFP is the limiting factor in the synthesis of the L3 fraction and, therefore, the absolute value of fucosylated AFP is extremely low, the conversion from L1 to L3 as judged by lectin immunoelectrophoresis represents a good marker for the progress of AR treatment.

show abstract

Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein

Cited by 36 publications

References 28 publications

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer

The Enzymatic Basis for the Conversion of Nonfucosylated to Fucosylated α-Fetoprotein by Acyclic Retinoid Treatment in Human Hepatoma Cells: Activation of α1-6 Fucosyltransferase

Contact Info

Product

Resources

About

Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein

Cited by 36 publications

References 28 publications

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer

The Enzymatic Basis for the Conversion of Nonfucosylated to Fucosylated &alpha;-Fetoprotein by Acyclic Retinoid Treatment in Human Hepatoma Cells: Activation of &alpha;1-6 Fucosyltransferase

Contact Info

Product

Resources

About

The Enzymatic Basis for the Conversion of Nonfucosylated to Fucosylated α-Fetoprotein by Acyclic Retinoid Treatment in Human Hepatoma Cells: Activation of α1-6 Fucosyltransferase